In recent years, advances in the field of immunology have led to a deeper understanding of how to harness the body’s own defenses to improve outcomes for patients with hematologic malignancies. Some of the most promising areas of research and emerging immunotherapies include tumor-specific T-cell–directed therapies, immunocheckpoint regulators, small molecule immunomodulatory drugs, specific antibodies that engage tumor and immune cells, and vaccines to neo-antigens. Of note, during the 2015 annual meeting of the American Society of Hematology, more than 200 abstracts were presented that relate to immunotherapies. With recent approvals of several immunotherapies for the treatment of hematologic malignancies, as well as many in development, it is crucial for researchers and clinicians to be informed about currently available agents, emerging research in immunotherapy, and ongoing clinical trials in order to achieve optimal outcomes for patients.
Friday, December 2, 2016 7:00 AM - 11:00 AMPacific Time
Hilton San Diego Bayfront1 Park BoulevardSan Diego, California 92101USA
This symposium is designed for hematologists and oncologists who diagnose and treat patients with hematologic malignancies, allied health care professionals involved with and/or interested in patients with hematologic malignancies, and researchers studying hematologic malignancies.
After completing this activity, participants should be better able to:
Interpret the clinical significance of recent advances in immunology and approved immunotherapies
Evaluate the current status and therapeutic potential of diverse immunotherapies for hematologic malignancies
Assess the safety and efficacy of immunotherapies and immunomodulatory drugs
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, The Leukemia & Lymphoma Society and Bio Ascend.
American Disabilities Act (ADA)
In compliance with the Americans with Disabilities Act, The UNMC Center for Continuing Education does not discriminate on the basis of disability. The Center shall provide reasonable accommodations, including auxiliary aids and services, to ensure equal access to its activities and services. If you would like an auxiliary aid or service, please call 1-888-476-9129 or e-mail firstname.lastname@example.org by 11/25/2016 with your request.
This activity is supported by The Leukemia & Lymphoma Society. Additional support is provided by educational grants from Acerta Pharma - A member of the AstraZeneca Group, Celgene Corporation, and KITE Pharma
This activity is a Friday Satellite Symposium on Immunotherapy: Transformation of Therapies for Blood Cancers preceding the 58th ASH Annual Meeting & Exposition.
Cvent Online Event Registration Software | Copyright © 2000-2017 Cvent, Inc. All rights reserved.